In this enlightening hybrid event, Prof Jenny Seligmann will share real-world insights and strategies, including how to navigate clinical complexities in CRC. Enhance your scientific understanding of optimal management in BRAF-mutant colorectal cancer (CRC). Key topics will include:
Attendees will also explore the sequencing of treatments for MSI-H/BRAF-mutant patients, the challenges of brain metastases, and the role of surgery and resectable disease management. Additional discussions will focus on the use of liquid biopsy/ctDNA, mechanisms of resistance, and future research priorities in BRAF V600E-mutant metastatic colorectal cancer. The session will be followed by a Q&A session.
Lunch provided for in-person participants.
Prof Tie's research interests are in clinical trials of novel therapeutics (early to late phase) and personalised cancer treatment for colorectal cancer (CRC), especially with the use of circulating tumour DNA (ctDNA). She is the principal investigator on many international clinical trials on novel therapy and leads several large national and international trials (DYNAMIC studies) using ctDNA to personalise treatment in localised CRC. She is also the lead investigator on the RESOLUTE trial assessing the benefit of integrating metastasis-directed local ablative therapies (surgery, stereotactic radiation, microwave ablation) with systemic treatment in oligometastatic CRC.
Prof Tie serves as the chair on the AGITG (Australasian Gastrointestinal Trials Group) Lower GI working party, member of AGITG’s Scientific Advisory Committee, ESMO Colorectal Tumour Faculty, several clinical trial steering committees, and the Cancer Adjudication Committee for the ASPREE (Aspirin in Reducing Events in the Elderly) international study.
Prof Seligmann is a highly-regarded clinician and researcher with interest in the personalisation of care in colorectal cancer. She is Chief Investigator of the international FOxTROT Platform and ARIEL trials and has a translational research program. Prof Seligmann is Co-Lead of the CRC-STARS research, focused on personalised medicine for bowel cancer, an international collaboration bringing together 40 research experts. She is also on the steering committee for the UK NCRI Colorectal Cancer Oncology Group and the European Society of Medical Oncology (ESMO) Lower GI faculty.
